Occurrence of Gastrointestinal Adverse Events Upon GLP-1 Receptor Agonist Initiation With Concomitant Metformin Use: A Post Hoc Analysis of LEADER, STEP 2, SUSTAIN-6, and PIONEER 6
Authors' conclusion
Concomitant metformin use does not increase occurrence of gastrointestinal symptoms during GLP-1RA initiation or impact GLP-1RA discontinuation.
Study context
- Population
- Participants of four clinical trials of liraglutide and semaglutide (LEADER, STEP 2, SUSTAIN-6, PIONEER 6) during GLP-1 RA initiation and titration
- Participants
- 16,996 participants4 trials
- Comparison
- Concomitant metformin use vs no metformin use during GLP-1 RA initiation and titration
- Metformin usersn = 12,928
- Primary endpoint
- Incidence of gastrointestinal adverse events during GLP-1 RA initiation and titration
Methodological detailspooled data from four clinical trials
- Pooled data from four clinical trials
Primary result
As reported in the abstract
Gastrointestinal adverse events · observation window
- Concomitant metformin use did not increase the percentage of participants with gastrointestinal adverse events or their severity
- Within treatment arms (GLP-1 RA and placebo), numerically higher percentage of metformin nonusers had gastrointestinal adverse events vs metformin users
Further findings
Study product discontinuation among participants with gastrointestinal adverse events
- Metformin use did not increase study product discontinuation
- Within treatment arms, numerically higher percentage of metformin nonusers discontinued study product vs metformin users
Original publication
Occurrence of Gastrointestinal Adverse Events Upon GLP-1 Receptor Agonist Initiation With Concomitant Metformin Use: A Post Hoc Analysis of LEADER, STEP 2, SUSTAIN-6, and PIONEER 6. Diabetes Care. Published 4 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →